Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 3/20 | 0.41 |
| ▸ | CCNH | P51946 | 3/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 3/20 | 0.39 |
| ▸ | CDK9 | P50750 | 6/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.39 |
| ▸ | CDK2 | P24941 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617951 | 0.80 | CDK1 (0.54) | CDK1KDRJAK2JAK1CDK7 | |
| SCHEMBL3620720 | 0.78 | JAK1 (0.49) | CDK1KDRJAK2JAK1CDK7 | |
| SCHEMBL3607870 | 0.77 | JAK1 (0.50) | ABL1PDGFRBCDK1KDRJAK2 | |
| SCHEMBL3620405 | 0.77 | CDK1 (0.55) | ABL1SRCPRKCDCDK1KDR | |
| SCHEMBL3618079 | 0.76 | SYK (0.49) | CDK1KDRJAK2JAK1CDK7 | |
| SCHEMBL3619953 | 0.75 | KDR (0.47) | PDGFRBPDGFRACDK1KDRJAK2 | |
| SCHEMBL3615782 | 0.71 | CDK1 (0.49) | ABL1SRCPRKCDCDK1KDR | |
| SCHEMBL8592858 | 0.71 | ABL1 (0.67) | ABL1PDGFRBBCRSRCPDGFRA | |
| SCHEMBL3622052 | 0.70 | CDK2 (0.54) | ABL1SRCPRKCDCDK1KDR | |
| SCHEMBL7124250 | 0.69 | ABL1 (0.48) | ABL1PDGFRBBCRSRCPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093776-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-04-15 | — | — | US | disclosed |
| US-20100093776-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-04-15 | — | — | US | disclosed |
| WO-2008079918-A1 | INDOL-4-YL-PYRIMIDINYL-2-YL-AMINE DERIVATIVES AND USE THEREOF AS CYCLIN DEPENDANT KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093776-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | ABL1 3215/4885PDGFRB 4797/4885BCR 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.